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(calculated from published data). US cost data (2009, dog owner’s perspective) were 
estimated from public sources. Health outcomes were expressed in days without 
symptoms of SP-W-A. All relevant input parameters were varied extensively in one-
way and probabilistic sensitivity analyses, and therapeutic “break points” in costs and 
outcome were determined. RESULTS: Cefovecin was more effective than amoxi/clav 
(162 versus 158 days without symptoms of SP-W-A). Up to a bodyweight (b.w.) of 
31 kg, cefovecin was dominant compared to amoxi/clav ($376.74 versus $382.34 
respectively for dogs with b.w. of 25 kg) when considering total therapy expenditure 
(incl. anamnesis, diagnosis, treatments). In large dogs, cefovecin was more costly; 
however, total therapy costs were only 6% higher than amoxi/clav. Outcomes were 
sensitive to changes of non-compliance, but remained robust when varying other 
parameters. CONCLUSIONS: Considering non-compliance with oral treatments as a 
cause of treatment failure, cefovecin’s higher drug and administration costs are totally 
or substantially offset by its better effectiveness leading to reduced costs for supple-
mentary treatments of relapses and failures.
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OBJECTIVES: To assess the cost-effectiveness of ﬂexible dosing with etanercept 
compared with adalimumab or inﬂiximab treatment in patients with moderate to 
severe psoriasis. METHODS: An economic model was constructed to estimate the 
incremental cost per quality adjusted life year for each therapy compared with no 
systemic therapy (NST). Patients met UK criteria for biologic treatment, which require 
both a Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index 
(DLQI)   10 at baseline. Initial response rates were taken from registration studies 
for each agent: quality of life gain associated with response from patient level data in 
etanercept studies. Adalimumab and inﬂiximab were given continuously in line with 
product licenses. Etancercept can be used ﬂexibly, with some patients experiencing 
drug free intervals between courses of therapy: UK observational data found that 64% 
of etanercept users experience such intervals, with the remainder having continuous 
therapy. Response and withdrawal rates were taken from clinical studies, and extrapo-
lated to a time horizon of 10 years. Costs were estimated from a UK payer perspective 
including drugs, administration visits and hospital stay for treatment failures. Stochas-
tic analysis was undertaken to quantify uncertainty. RESULTS: The model estimated 
incremental cost-effectiveness ratios (ICER) of each therapy compared with NST to 
be: £12,600 (95% CI: £10,131, 14,066) for etanercept ﬂexible dosing; £17,975 
(£17,779, 31,106) for continuous adalimumab and £44,377 (£44,038, 73,815) for 
continuous inﬂiximab. The ICER for etanercept therapy was sensitive to the frequency 
and duration of drug free intervals in these patients but was below the ICER for con-
tinuous therapies. CONCLUSIONS: The model found ﬂexible dosing with etanercept 
to be more cost-effective than continuous therapy, as it allows control to be main-
tained at lower drug cost. This ﬁnding is consistent with a previous publication (Sitzo 
2008), but has now been conﬁrmed with drug utilisation data from UK practice.
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OBJECTIVES: This study aimed to estimate the cost per treatment failure avoided of 
topical preservative-free moxiﬂoxacin (MOXI) as compared with oﬂoxacin (OFLOX), 
marketed as preserved Traﬂoxal and preservative free Traﬂoxal E.D.O.in the treat-
ment of acute infectious conjunctivitis in The Netherlands (NL). METHODS: A survey 
amongst GPs and Ophthalmologists (OPH) collected health care resources(HCU) used 
to manage acute bacterial conjunctivitis. Cost of health care resourses were obtained 
from National databases; treatment failure rates were estimated from a meta-analysis 
of randomized controlled trials(RCT) investigating MOXI. A decision tree model in 
Treeage was populated to deﬁne the cost per treatment failure avoided using MOXI 
instead of OFLOX. OFLOX treatment failure rate was obtained from a trial directly 
comparing OFLOX with MOXI. Probabilistic sensitivity analysis was performed 
investigating the range of HCU used in clinical practice by different OPH and inves-
tigating the uncertainty around treatment failures reduction. RESULTS: The average 
estimated incremental cost per treatment failure avoided by a GP was a53.47 and 
a215a by an OPH (range a169.55a to a279.42). The treatment failure rate for MOXI 
was 2.9% [with 95% CI 1.4%,4.3%] versus 7.6% for OFLOX. The price for MOXI 
taken in the model was a14.04, the maximum reimbursement of current preservative 
free antibiotic treatments in NL. A weighted current average price of Traﬂoxal 
(110,943 units) and Traﬂoxal E.D.O.(15,554 units) was a3.74. With a failure rate less 
than half that for OFLOX, and assuming a willingness to pay (WTP) of 100a per 
treatment failure avoided (based on the WTP for avoiding allergic reactions), in 90% 
of the simulations MOXI is cost-effective. CONCLUSIONS: Use of topical moxiﬂoxa-
cin instead of oﬂoxacin avoids treatment failures. Moxiﬂoxacin, with a price of 14,04a 
is a cost-effective alternative to oﬂoxacin given a willingness to pay of a100 per treat-
ment failure avoided.
PSS22
COST-EFFECTIVENESS STUDY OF COMPLICATED SKIN AND  
SKIN-STRUCTURE INFECTION TREATMENT IN MEXICO
Baca-Muro VI1, Soria-Cedillo IF2, Olvera K3, Garcia-Contreras F4
1Research Consulting, Puebla, Mexico, 2Research Consulting, Hacienda Ojo de Agua, Mexico, 
3Novartis Farmaceutica México, Mexico D.F., Mexico, 4Instituto Mexicano de Seguro Social, 
Mexico D.F., Mexico
OBJECTIVES: To determine the most cost-effective intravenous antibiotic treatment 
for complicated skin and skin-structure infections (cSSI) in public health care institu-
tions in Mexico. METHODS: A cost-effectiveness study with institutional perspective 
was conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin 
(VAN) or i.v. Linezolid (LIN) as ﬁrst-line and/or second-line antibiotic therapy. Data 
was collected from a systematic review which included the most recent published 
articles measuring clinical improvement, length of stay at hospital services and adverse 
events due to the use of any of three alternatives. A decision tree with Bayesian 
approach was designed to simulate the use of resources based on patient’s prognosis 
considering clinical success as the best health state, reached in either short hospital 
stay or long hospital stay, and a therapeutic failure of ﬁrst-line antibiotic therapy 
(DAP, VAN or LIN) which caused the use of a second-line antibiotic therapy (DAP 
or LIN depending on ﬁrst election). Costs calculation considered hospital stay, con-
comitant medication and selected antibiotic treatment. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of the most uncertain variables. 
RESULTS: The use of DAP as ﬁrst-line therapy results in the lowest cost per clinical 
success (CS) (DAP: US$3,405.00/CS; VAN: US$3,550.00/CS; LIN: US$3,870.00/CS). 
In case of therapeutic failure of DAP, the use of LIN as second-line therapy resulted 
in the lowest total cost per clinical success (DAP-LIN: US$3,255.00/CS; VAN-DAP: 
US$3,310.00/CS; VAN-LIN: US$3,310.00/CS; LIN-DAP: US$3,423.00), reaching 
98% of CS. The sensitivity analysis varying clinical success rates of every evaluated 
alternative conﬁrmed the robustness of base study. CONCLUSIONS: Daptomycin is 
the most cost-effective alternative in the treatment of cSSI when used as ﬁrst-line 
antibiotic therapy since its use reduces the length of hospital stay reducing expenses 
of public health system budget in Mexico.
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OBJECTIVES: The purpose was to conduct a cost-effectiveness analysis (CEA) of 
imiquimod therapy compared to no treatment in patients with actinic keratoses (AKs) 
in Poland. METHODS: The analysis was based on a decision model regarding clinical 
effects of imiquimod therapy in comparison to placebo (vehicle cream), determined in 
randomized clinical trials. The population was deﬁned as adult patients with actinic 
keratoses, without hypertrophy and keratosis, with typical course (localisation on 
head skin), competent immune system of patient, when another treatment is contra-
indicated or inappropriate. Complete clearance was assessed as health outcome. Direct 
medical costs of the analyzed therapies were estimated from the perspective of both 
payers in Poland (National Health Fund and patient). Costs of medication and clinic 
visits were included. Time horizon of the analysis was 20 weeks. Treatment was 
assumed as once a day 3x/week, one or two 4-week cycles. Costs and effects were not 
discounted. RESULTS: Ratio of complete clearance was 0.620 for patients treated 
with imiquimod and 0.080 for patients taking placebo. Total costs of imiquimod 
therapy were estimated at 602.26 PLN, while costs of no treatment were 128.26 PLN. 
Incremental cost-effectiveness ratio (ICER) for the comparison of imiquimod versus 
placebo was calculated as 878 PLN per gained complete clearance. CONCLUSIONS: 
Imiquimod is more effective and more expensive than no treatment in patients with 
actinic keratoses. ICER value is below the acceptable threshold, therefore imiquimod 
therapy is considered as cost-effective treatment in Poland.
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OBJECTIVES: Glaucoma is associated with elevated intraocular pressure (IOP) which 
can develop nerve damage and loss of vision. Primary open angle glaucoma (POAG) 
or ocular hypertension (OH) patients should be treated with lowering IOP that is a 
major factor in preventing the progression of visual impairment related to glaucoma. 
Nowadays prostaglandin is recommended as ﬁrst-line treatment drug for reduction of 
elevated IOP. The main objective of this study is to evaluate the cost-effectiveness of 
taﬂuprost compared with latanoprost in POAG or OH patients in Korea. METHODS: 
A decision analytic model was developed from a societal perspective for one year to 
estimate clinical outcome, drug cost and glaucoma related cost. The model assumes 
pathways like following: successful treatment, switching to other drug, adding other 
drug, laser or surgery. Transition probabilities of successful treatment is deﬁned as 
the percentage of patients with elevated IOP achieving 20% reduction, and transition 
probabilities of switching is the percentage of patients who were withdrawn due to 
severe adverse events. IOP reduction rate and transition probabilities were obtained 
from published literatures searched in database. Resource utilizations and costs were 
calculated with Korean national health insurance data and clinical expert opinions. 
Sensitivity analyses were performed on crucial parameters. RESULTS: Taﬂuprost is 
